rss
Br J Ophthalmol 96:10-13 doi:10.1136/bjophthalmol-2011-300183
  • Innovations

Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy

  1. Rishi P Singh
  1. Department of Ophthalmology, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
  1. Correspondence to Dr Rishi P Singh, Cole Eye Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, i-32, Cleveland OH 44195, USA; singhr{at}ccf.org

  1. Contributors All authors contributed to the writing and editing of this manuscript.

  • Accepted 27 June 2011
  • Published Online First 3 November 2011

Abstract

Chronic central serous retinopathy (CSR) is characterised by frequent exacerbations and a poor visual prognosis. Very few therapies exist for chronic CSR, and the existing therapies are often ineffective. Thus, novel therapies to combat this frustrating disorder are needed. Presented here is a case detailing a patient with chronic CSR with persistent subfoveal fluid of 2 years' duration that completely resolved with 1 month of oral rifampin therapy. As a cytochrome P450, 3A4 inducer, rifampin is thought to favourably alter the metabolism of endogenous steroids, thereby leading to an improvement in CSR manifestations.

Footnotes

  • Competing interests None.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Responses to this article

  • CSR or TB?
    • Khawaja K Shoaib
    Br J Ophthalmol published online January 19, 2012

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All Versions of this Article:
    1. bjophthalmol-2011-300183v1
    2. 96/1/10 most recent

Social bookmarking

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.